Abstract
Backgrounds: There is variable literature on the rates of IBI and UTI in febrile infants (<90 days) whenviral panels are positive for SARS-CoV-2 (COVD19). We aimed to assess the rates of IBI and UTI in febrile infants presenting to emergency departments across the UK with concurrent COVD19 infection.
Methods: The FIDO study is large prospective multicentre observational study looking at the evaluation of febrile infant on behalf of the Paediatric Emergency UK and Ireland (PERUKI) network. It is currently collecting data from 27 sites across the UK. Infants up to 90 days of age attending between 01/08/2022 -16/01/2023 were screened for inclusion. Infants with a recorded fever (≥38°C) prior to presentation were eligible for inclusion. There were no exclusion criteria. Disposition outcomes and rates of IBI and UTI were reported for infants with positive COVID19.
Results: Of the 240 patients undergoing viral panel testing, 40 (17%) were COVID19 positive. The median age for the COVID19 cohort was 48 days (IQR: 30 – 60) with females making up 55%. The median absolute neutrophil count was 3.7x109/L (IQR: 2.2 – 5.7) while the median C-reactive protein was9mg/L (IQR: 2 – 23). About 90% underwent bloods, 68% urinalysis and culture, and 40% had a lumbar puncture performed in the COVID19 cohort. Of the 40 patients, 5 (12.5%) were discharged home directly from ED. In the entire cohort of patient undergoing viral testing (240) the UTI rate was 8.3% and IBI rate was 3.8%. However, no patient with positive COVID19 test had UTI or IBI.
Conclusions/Learning Points: In this study, the concurrent risk of IBI and UTI in patients with positive COVID19 status was negligible. We would advocate a tailored approach to the management of these patients.
Methods: The FIDO study is large prospective multicentre observational study looking at the evaluation of febrile infant on behalf of the Paediatric Emergency UK and Ireland (PERUKI) network. It is currently collecting data from 27 sites across the UK. Infants up to 90 days of age attending between 01/08/2022 -16/01/2023 were screened for inclusion. Infants with a recorded fever (≥38°C) prior to presentation were eligible for inclusion. There were no exclusion criteria. Disposition outcomes and rates of IBI and UTI were reported for infants with positive COVID19.
Results: Of the 240 patients undergoing viral panel testing, 40 (17%) were COVID19 positive. The median age for the COVID19 cohort was 48 days (IQR: 30 – 60) with females making up 55%. The median absolute neutrophil count was 3.7x109/L (IQR: 2.2 – 5.7) while the median C-reactive protein was9mg/L (IQR: 2 – 23). About 90% underwent bloods, 68% urinalysis and culture, and 40% had a lumbar puncture performed in the COVID19 cohort. Of the 40 patients, 5 (12.5%) were discharged home directly from ED. In the entire cohort of patient undergoing viral testing (240) the UTI rate was 8.3% and IBI rate was 3.8%. However, no patient with positive COVID19 test had UTI or IBI.
Conclusions/Learning Points: In this study, the concurrent risk of IBI and UTI in patients with positive COVID19 status was negligible. We would advocate a tailored approach to the management of these patients.
Original language | English |
---|---|
Publication status | Published - 09 May 2023 |
Event | 41st Annual Meeting of the European Society of Paediatric Infectious Diseases 2023 - Lisbon, Portugal Duration: 08 May 2023 → 12 May 2023 https://2023.espidmeeting.org/ |
Conference
Conference | 41st Annual Meeting of the European Society of Paediatric Infectious Diseases 2023 |
---|---|
Abbreviated title | ESPID 2023 |
Country/Territory | Portugal |
City | Lisbon |
Period | 08/05/2023 → 12/05/2023 |
Internet address |